NEW DELHI: India's most populous state of Uttar Pradesh will spend up to US$1 billion to buy COVID-19 shots and held early talks this week with companies such as Pfizer and the local distributor of Russia's Sputnik V, a state official said on Thursday (May 13).
The move by Uttar Pradesh, home to more people than Brazil, comes as many Indian states curtail vaccinations due to severe shortages amid a record surge in coronavirus infections, with India recording more than 4,000 deaths for a second straight day as its health system fails to cope.
READ: India reports more than 4,000 COVID-19 deaths for second straight day
READ: Bodies float down Ganges as nearly 4,000 more die of COVID-19 in India
Uttar Pradesh has also held pre-bid talks with Indian vaccine companies the Serum Institute of India - licensed to make the AstraZeneca and Novavax shots - Bharat Biotech and Cadila Healthcare as part of a global tender to buy 40 million doses over the next few months, state spokesman Navneet Sehgal told Reuters.
He said Johnson and Johnson could also confirm their participation in the tender by late Thursday via email. Sputnik V's local distributor, Dr Reddy's Laboratories, has also held talks.
"Money is not an issue, we have a huge budget," said Sehgal, a senior bureaucrat in the state of 240 million people. "We will spend up to 100 billion rupees (US$1.36 billion)."
He said funds would have to be diverted from other areas to buy the vaccines.
BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
https://news.google.com/__i/rss/rd/articles/CBMiamh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy9hc2lhL2luZGlhLXV0dGFyLXByYWRlc2gtMS1iaWxsaW9uLXZhY2NpbmVzLXBmaXplci1zcHV0bmlrLXYtMTQ4MDI2MTLSAQA?oc=5
2021-05-13 11:06:57Z
CBMiamh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy9hc2lhL2luZGlhLXV0dGFyLXByYWRlc2gtMS1iaWxsaW9uLXZhY2NpbmVzLXBmaXplci1zcHV0bmlrLXYtMTQ4MDI2MTLSAQA
Tidak ada komentar:
Posting Komentar